First People's Hospital

Acetazolamide Levamisole (CJVICC-001) is a small-molecule oral combination therapy under development by The First People's Hospital of Lianyungang for hepatocellular carcinoma (HCC). The program combines acetazolamide (a carbonic anhydrase inhibitor marketed as DIAMOX) with levamisole in a novel therapeutic approach. Currently in Phase 3 development, the program remains active with the most recent milestone recorded on 2 November 2020. Acetazolamide itself is an established, approved medication with extensive regulatory history in both the United States and Australia, marketed by multiple generic manufacturers including Accord Healthcare, Teva, and others. The combination therapy represents a repurposing strategy leveraging an existing approved agent. The program is being evaluated through clinical trial NCT04611373. No mechanism of action, specific target, or lead investigator information has been disclosed. Peak sales projections and consensus positioning remain undisclosed. The development status indicates active ongoing work, though specific recent milestones beyond November 2020 have not been publicly reported.

Hepatocellular carcinoma remains a significant global health burden with limited treatment options and poor prognosis in advanced stages. The competitive landscape for HCC is crowded with multiple Phase 3 programs from major pharmaceutical companies including Roche, AstraZeneca, Tempest Therapeutics, and Novartis, employing diverse mechanisms including checkpoint inhibitors, tyrosine kinase inhibitors, and combination immunotherapies. This acetazolamide-levamisole combination represents a potential alternative approach using repurposed agents, which could offer advantages in cost, manufacturing, and potentially tolerability compared to novel biologics. The patient population with HCC is substantial globally, particularly in Asia where hepatitis B and C prevalence drive disease incidence. The commercial significance of HCC therapeutics is substantial, with multiple approved and pipeline agents commanding premium pricing. However, the acetazolamide-levamisole approach faces significant competitive pressure from well-resourced competitors with established clinical data and regulatory relationships. The program's academic sponsorship by a Chinese hospital suggests potential focus on Asian markets and healthcare systems where cost-effective therapies are prioritized. Success would depend on demonstrating efficacy and safety advantages over existing and emerging competitors in head-to-head or comparative effectiveness contexts.

Drug Class: Small-molecule combination therapy

Components:

• Acetazolamide (DIAMOX): Carbonic anhydrase inhibitor; oral administration
• Levamisole: Immunomodulatory agent; mechanism in HCC not specified

Modality: Small-molecule oral combination

Route of Administration: Oral

Mechanism of Action: Not yet disclosed for the combination

Target: Not yet disclosed

Acetazolamide Regulatory Status: Approved in the United States (multiple ANDA approvals from 1995–2021 across 30+ manufacturers including Accord Healthcare, Teva, Aurobindo, Zydus, and others) and Australia (PBS code 1004W, approved April 2005 by Arrow Pharma). Established safety and pharmacokinetic profile.

Patent Status: Not disclosed for the combination formulation

Acetazolamide Component:

• United States FDA: Approved; 32 ANDA applications approved from 1995–2021 (NDA008943, NDA012945 for original approvals; multiple subsequent ANDAs). Marketed by 30+ generic manufacturers.
• Australia TGA: Approved; PBS code 1004W; Arrow Pharma Pty Ltd listing effective 1 April 2005.

Acetazolamide Levamisole Combination (CJVICC-001):

• Regulatory Status: Not yet disclosed for any jurisdiction
• FDA: Status not disclosed; Phase 3 trial NCT04611373 registered but approval pathway not specified
• EMA: Status not disclosed
• PMDA (Japan): Status not disclosed
• NMPA (China): Status not disclosed; sponsor is Chinese institution suggesting potential China-focused development

No filing dates, breakthrough designations, or regulatory interactions have been disclosed.

Strategic Positioning: The acetazolamide-levamisole combination represents a repurposing strategy leveraging established, generic-available agents. This approach offers potential cost advantages and simplified manufacturing compared to novel biologics, particularly relevant for Asian healthcare systems. However, the lack of disclosed mechanism of action and target raises questions about the scientific rationale and differentiation strategy.

Competitive Implications: The program faces intense competition from well-resourced multinational companies with established clinical data and regulatory relationships. Checkpoint inhibitor combinations (particularly atezolizumab + bevacizumab, durvalumab combinations) have demonstrated clinical benefit and are advancing rapidly. The acetazolamide-levamisole approach must demonstrate clear efficacy advantages or address unmet needs (e.g., tolerability, access, cost) to compete effectively. The absence of recent disclosed milestones since November 2020 suggests either slower-than-expected enrollment or limited clinical progress communication.

Development Gaps: Critical information remains undisclosed: mechanism of action for the combination, specific target, lead investigator, trial design details, enrollment status, and interim efficacy/safety data. These gaps limit assessment of scientific merit and competitive positioning.

Future Catalysts: Key milestones would include Phase 3 trial enrollment completion, interim efficacy readouts, regulatory interactions with FDA or NMPA, and publication of trial design/rationale in peer-reviewed literature. Comparative effectiveness data versus checkpoint inhibitor combinations would be critical for competitive positioning.